Join us at the EULAR 2022 rheumatology congress
We’re delighted to be attending this year’s EULAR congress in Copenhagen, Denmark, which for the first time since 2019 will be held in-person as well as virtually. Janssen will have a strong presence throughout the congress, so we hope you can join us there!
What to expect from
TREMFYA®
Looking to learn more about how TREMFYA® could provide unquestionable joint efficacy [1] for your PsA patients? Join us at our booth to speak to one of our representatives, or delve deeper with an immersive, interactive
experience.
New data being released at EULAR
Early significant effects of guselkumab on pain were enhanced through 1 year. Significant predictors of change in pain were consistent at Week 24 and Week 52, with the exception of mental health measures. The impact of mental status on patient-reported pain and the potential for guselkumab to improve pain in patients with fibromyalgia warrant further consideration.
In bio-naïve patients with active psoriatic arthritis and investigator-confirmed sacroiliitis, guselkumab provided durable improvements in axial symptoms through Week 100, with substantial proportions of patients achieving and maintaining clinically meaningful improvements.
The favorable guselkumab safety profile demonstrated through Week 24 persisted through 2 years across bio-naïve and TNFi-experienced patients.
Discover how you could provide your PsA patients with lasting, consistent relief[^1] at EULAR
For the 66% of PsA patients suffering from persistent joint pain [5]
For the 35-50% of patients with PsA discontinuing TNF or IL-17 inhibitors within the first year due to treatment failure [6][7]
For the 80% of PsA patients with active skin psoriasis [8]
Don’t miss out
Check back here after the congress to see the highlights!
Resources
An interview with Prof. Jean Dudler
An interview with Dr David Keifer
An overview of TREMFYA®’s mode of action
Discover more about TREMFYA® in PsA on the Janssen Medical Cloud
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See [insert local reporting URL/organisation] for how to report side effects.
IL, interleukin; PsA, psoriatic arthritis; TNF, Tumor necrosis factor.
